Author Affiliations: Mt Zion Carol Franc Buck Breast Care Center, University of California, San Francisco (Dr Esserman); and Division of Hematology and Oncology, Northwestern University, Chicago, Illinois (Dr Kaklamani).
The study reported by Domchek and colleagues1 in this issue of JAMA demonstrates the benefit of risk-reducing procedures for women with strong genetic predispositions for breast cancer. This multicenter study involved almost 2500 women diagnosed with BRCA gene mutations, almost half of whom chose either risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing mastectomy (RRM). None of the women who underwent RRM developed breast cancer. Among women who underwent RRSO, only 1.1% developed ovarian cancer. Importantly, RRSO was associated with a reduction in all-cause mortality (hazard ratio [HR], 0.40), breast cancer–specific mortality (HR, 0.44), and ovarian cancer–specific mortality (HR, 0.21).
Esserman L, Kaklamani V. Lessons Learned From Genetic Testing. JAMA. 2010;304(9):1011-1012. doi:10.1001/jama.2010.1263